Y-mAbs Plans IPO to Advance Two Pediatric Cancer Drugs to the FDA

Neuroblastoma, a rare pediatric cancer, has no FDA-approved treatments for patients who relapse after the first line of therapies. Y-mAbs has developed two experimental antibody drugs for the disease and it is lining now lining up an IPO to as it readies both therapies for submission to the FDA for approval.